Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer

Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Erb, Holger H. H., Bodenbender, Julia, Handle, Florian, Diehl, Tamara, Donix, Lukas, Tsaur, Igor, Gleave, Martin, Haferkamp, Axel, Huber, Johannes, Fuessel, Susanne, Juengel, Eva, Culig, Zoran, Thomas, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425943/
https://www.ncbi.nlm.nih.gov/pubmed/32790723
http://dx.doi.org/10.1371/journal.pone.0237248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425943/
https://www.ncbi.nlm.nih.gov/pubmed/32790723
http://dx.doi.org/10.1371/journal.pone.0237248

Ejemplares similares